United States Endobronchial Ultrasound Biopsy Market Report by Product, Application, End Use, States and Company Analysis, 2026-2034

United States Endobronchial ultrasound biopsy Market Size and Forecast 2026-2034

United States Endobronchial ultrasound biopsy Market is expected to reach US$ 371.02 Billion by 2034 from US$ 257.09 Billion in 2025, with a CAGR of 4.16% from 2026 to 2034. Rising lung cancer incidence, growing need for minimally invasive diagnosis and staging, increasing EBUS adoption, advances in ultrasound bronchoscopes, molecular testing requirements, single-use technologies, and expanding ambulatory procedures are driving market growth.

United States Endobronchial ultrasound biopsy Industry Overview

The United States endobronchial ultrasound (EBUS) biopsy industry is expanding as healthcare providers increasingly adopt minimally invasive techniques for diagnosing and staging lung diseases. EBUS-guided transbronchial needle aspiration (EBUS-TBNA) enables physicians to visualize mediastinal and hilar lymph nodes using ultrasound integrated with bronchoscopy and obtain tissue samples during the same procedure. The technology has become an important approach for initial lung cancer diagnosis and staging, particularly because tissue samples can subsequently undergo histopathological and molecular analysis. The American College of Chest Physicians describes EBUS-TBNA as a standard approach for initial lung cancer diagnosis and staging and recommends evidence-based practices for specimen acquisition and handling. Growing demand for less invasive procedures, earlier cancer diagnosis, and accurate staging is supporting utilization across hospitals, cancer centers, and specialized pulmonary units.

Technological development is broadening the capabilities of EBUS procedures. Modern ultrasound bronchoscopes combine high-resolution imaging with needle-access capabilities, while improvements in bronchoscopy platforms, biopsy needles, processors, visualization systems, and single-use devices are supporting procedural efficiency. FDA records show continued regulatory activity in this category. In August 2026, an Olympus EVIS EUS ultrasound bronchofibervideoscope received a substantially equivalent 510(k) decision, demonstrating continuing development of ultrasound bronchoscopy platforms. In July 2026, the FDA also cleared Cook's EchoTip Ultra Endobronchial HD Ultrasound Biopsy Needle and EchoTip ProCore Endobronchial HD Ultrasound Biopsy Needle for Fujifilm scopes. These developments indicate continued investment in equipment and accessories designed to improve sampling capabilities and compatibility across bronchoscopic systems.

The market is also being influenced by the increasing importance of obtaining adequate tissue for molecular testing. Modern lung cancer management frequently requires biomarker information to support targeted treatment decisions, making specimen quality and preservation increasingly important. CHEST recommends rapid on-site evaluation in suspected malignant disease and recommends four or more needle passes, reflecting the importance of optimizing specimen acquisition. The respiratory endoscopy ecosystem is simultaneously moving toward single-use devices, advanced visualization, peripheral access, and complementary biopsy technologies. In August 2026, Olympus announced a distribution agreement with Endocision for a portable single-use respiratory cryobiopsy system, with U.S. commercial launch expected in 2027; Olympus specifically identified the agreement as an expansion of its respiratory portfolio alongside EBUS and radial EBUS technologies. Together, cancer screening, molecular diagnostics, technology innovation, and demand for minimally invasive procedures are creating favorable conditions for sustained U.S. EBUS biopsy market development.

Growth Drivers for the United States Endobronchial ultrasound biopsy Market

Growing Lung Cancer Burden Strengthens Diagnostic Demand

The increasing need to diagnose, stage, and characterize lung cancer represents a fundamental growth driver for EBUS biopsy procedures. EBUS-TBNA provides minimally invasive access to mediastinal and hilar lymph nodes, enabling clinicians to obtain tissue for diagnosis and staging without relying exclusively on more invasive surgical approaches. Its clinical value becomes particularly important when treatment decisions depend on accurate assessment of lymph-node involvement and disease extent. The availability of tissue for additional molecular testing further strengthens EBUS utilization because modern lung cancer management increasingly requires biomarker information. CHEST identifies EBUS-TBNA as a standard method for initial lung cancer diagnosis and staging and recommends collecting additional specimens for molecular analysis when appropriate. As oncology programs increasingly emphasize accurate staging, personalized treatment, and minimally invasive procedures, hospitals and pulmonary centers are likely to continue investing in EBUS platforms, needles, processors, and associated pathology workflows.

Demand for Minimally Invasive and Image-Guided Procedures

Healthcare providers are increasingly favoring diagnostic procedures that can obtain clinically useful tissue while limiting surgical intervention, hospitalization, and patient recovery requirements. EBUS supports this trend by combining bronchoscopy with real-time ultrasound visualization, allowing physicians to target lymph nodes and other structures during a single procedure. The technology can improve procedural guidance compared with conventional bronchoscopy alone and can facilitate tissue acquisition from areas that may otherwise require more invasive approaches. Continued improvements in imaging quality, ultrasound processors, bronchoscopic maneuverability, needle design, and disposable accessories can further strengthen physician confidence. FDA classification describes ultrasound bronchoscopes as devices incorporating an ultrasound transducer at the distal end to visualize and access the bronchial tree and lungs. The growing preference for outpatient and minimally invasive interventions also supports demand from specialized pulmonary departments and ambulatory surgical facilities. As healthcare systems prioritize efficient care pathways, EBUS can provide an attractive combination of visualization, biopsy, and diagnostic staging.

Molecular Diagnostics Increase the Value of Adequate Tissue Samples

The increasing importance of molecular diagnostics in lung cancer treatment is strengthening demand for biopsy technologies capable of obtaining adequate and appropriately preserved specimens. Targeted therapies and personalized oncology require identification of specific molecular characteristics, meaning tissue obtained during bronchoscopy may need to support histopathology, immunohistochemistry, and molecular testing. CHEST's EBUS-TBNA guideline emphasizes specimen collection and processing practices designed to optimize diagnostic yield and downstream ancillary testing. It recommends rapid on-site evaluation in suspected malignant disease and four or more needle passes under specified circumstances. Advances in biopsy needles and sampling technologies are responding to these requirements. The FDA's 2026 clearance of Cook's EchoTip Ultra and EchoTip ProCore endobronchial ultrasound biopsy needles illustrates continuing development of tools designed for ultrasound-guided tissue acquisition. As molecular profiling becomes increasingly embedded in lung cancer pathways, the ability to obtain high-quality samples efficiently should continue supporting EBUS adoption.

Challenges in the United States Endobronchial ultrasound biopsy Market

High Equipment Costs and Specialized Clinical Expertise

EBUS biopsy systems require substantial investment in ultrasound bronchoscopes, processors, visualization equipment, biopsy needles, accessories, maintenance, and supporting procedural infrastructure. Healthcare facilities must also establish appropriate bronchoscopy rooms, anesthesia capabilities, pathology workflows, and infection-control procedures. These requirements can make EBUS adoption more difficult for smaller hospitals and facilities with relatively low procedure volumes. In addition, successful EBUS-TBNA requires specialized training and experience because physicians must navigate the bronchial tree, identify anatomical structures using ultrasound, select appropriate sampling locations, and obtain sufficient tissue. Pathology and laboratory teams must also be capable of processing specimens for histological and molecular analysis. Training requirements can increase implementation costs and create dependence on experienced interventional pulmonologists. As the technology becomes more sophisticated, facilities may also need to upgrade imaging processors and compatible bronchoscopic equipment. Consequently, capital expenditure, workforce availability, training, and procedural volume remain important barriers to broader adoption, particularly outside major metropolitan healthcare systems.

Device Safety, Reprocessing, and Procedural Complexity

Device safety and infection-control requirements represent another challenge for the EBUS biopsy market. Reusable bronchoscopes require validated cleaning and reprocessing workflows, while single-use devices can increase per-procedure expenditure. Healthcare providers must balance infection-control advantages, equipment utilization, and operating costs when selecting reusable or disposable technologies. Device-related safety events can also affect market confidence. In January 2026, Olympus expanded a voluntary recall of all lots of its ViziShot 2 FLEX 19G EBUS-TBNA needles after investigating complaints involving component ejection or detachment during procedures, including reports of patient injury and one death. Such events highlight the importance of rigorous device design, quality management, clinician training, and post-market surveillance. Procedural complexity can also affect procedure times and resource requirements, particularly when adequate tissue must be obtained for multiple downstream tests. Manufacturers therefore need to demonstrate reliable performance, safety, compatibility, and clinical utility while providers must maintain appropriate training and quality-control programs.

California Endobronchial Ultrasound Biopsy Market - Advanced Pulmonary Care and Oncology

California represents a strong market for EBUS biopsy because of its large healthcare system, extensive cancer-care infrastructure, academic medical centers, and concentration of specialized pulmonary and thoracic oncology programs. Major metropolitan areas including Los Angeles, San Francisco, San Diego, and Sacramento contain hospitals capable of supporting advanced bronchoscopy, interventional pulmonology, pathology, and molecular diagnostics. The state's strong biotechnology ecosystem also encourages integration between diagnostic technologies and precision oncology. EBUS-TBNA is particularly valuable in lung cancer pathways because samples can support both staging and downstream molecular testing. California's large population and extensive healthcare network create significant procedure volumes, while technology-focused institutions are more likely to adopt advanced imaging systems, peripheral EBUS, and newer biopsy accessories. The state also has substantial outpatient healthcare infrastructure, supporting potential migration of selected procedures toward ambulatory settings. However, equipment costs, specialist availability, reimbursement variation, and access disparities can influence adoption across different healthcare facilities.

Texas Endobronchial Ultrasound Biopsy Market - Large Healthcare Networks and Cancer Centers

Texas has substantial potential for EBUS biopsy due to its large population, extensive hospital networks, and concentration of major cancer and pulmonary care institutions. Houston, Dallas-Fort Worth, Austin, and San Antonio host advanced healthcare facilities with interventional pulmonology, thoracic surgery, pathology, and molecular diagnostic capabilities. EBUS is increasingly important within lung cancer diagnostic pathways because physicians can use ultrasound-guided needle aspiration for minimally invasive lymph-node sampling and staging. The presence of large academic hospitals and comprehensive cancer centers supports adoption of sophisticated bronchoscopic technologies and advanced tissue-processing workflows. Texas' growing healthcare infrastructure also creates opportunities for ambulatory procedural centers and specialty pulmonary practices. Demand for EBUS equipment can increase as providers seek technologies that support rapid diagnosis and precision oncology. Nevertheless, access to highly trained interventional pulmonologists can vary geographically, and smaller facilities may face challenges associated with capital expenditure, procedure volumes, pathology infrastructure, and ongoing device maintenance.

New York Endobronchial Ultrasound Biopsy Market - High-Density Specialty Care Environment

New York represents an important EBUS biopsy market because of its concentration of academic medical centers, major hospitals, comprehensive cancer centers, and specialized pulmonary programs. New York City in particular provides a dense healthcare ecosystem with strong demand for advanced diagnostic and interventional procedures. EBUS-TBNA supports lung cancer diagnosis and mediastinal staging while providing tissue that can be evaluated through pathology and molecular testing. The state's sophisticated oncology infrastructure encourages adoption of advanced bronchoscopy systems, ultrasound processors, biopsy needles, and complementary navigation technologies. Research institutions also contribute to clinical studies and innovation in interventional pulmonology. High procedure volumes at tertiary hospitals can support investment in advanced EBUS systems and specialized staff. The market may also benefit from increasing use of molecularly guided lung cancer therapies requiring adequate tissue samples. However, healthcare operating costs, reimbursement pressures, training requirements, and competition for specialized physicians can affect expansion across the state.

Florida Endobronchial Ultrasound Biopsy Market - Growing Demand for Pulmonary Diagnostics

Florida offers attractive opportunities for EBUS biopsy due to its large and aging population, expanding healthcare infrastructure, and growing demand for pulmonary and oncology services. Metropolitan areas including Miami, Tampa, Orlando, and Jacksonville contain hospitals, cancer centers, pulmonary practices, and diagnostic facilities capable of performing advanced bronchoscopic procedures. EBUS can support minimally invasive diagnosis and staging of lung cancer while reducing reliance on more invasive surgical approaches in appropriate patients. Florida's extensive outpatient healthcare network also creates opportunities for selected bronchoscopic procedures to move toward ambulatory settings where clinical and reimbursement conditions permit. Growing adoption of molecular testing further increases the value of tissue obtained through EBUS because samples may be required for biomarker analysis and treatment selection. Providers nevertheless need specialized interventional pulmonologists, trained bronchoscopy teams, pathology support, and appropriate equipment. Geographic differences in healthcare access and capital availability may therefore influence adoption between major urban centers and smaller communities.

EBUS Scopes - Core Visualization and Sampling Platforms

The EBUS Scopes Market represents the central equipment segment supporting endobronchial ultrasound-guided biopsy procedures. These specialized bronchoscopes incorporate ultrasound transducers that enable clinicians to visualize structures surrounding the airways and guide needle sampling of lymph nodes and lesions. The segment includes conventional convex-probe EBUS scopes, newer peripheral EBUS technologies, reusable systems, and emerging single-use bronchoscopic platforms. Manufacturers are focusing on image quality, maneuverability, working-channel design, ergonomics, compatibility, and integration with advanced visualization systems. Olympus has identified EBUS scopes and EBUS-TBNA needles as important respiratory product categories and has scheduled a peripheral EBUS scope for U.S. launch within its FY2027 product roadmap. FDA regulatory activity also demonstrates continuing development of ultrasound bronchoscopes, including the August 2026 510(k) decision for an Olympus EVIS EUS ultrasound bronchofibervideoscope. Continued innovation and replacement of aging systems should support this equipment segment.

Infection Diagnostics - Expanding Role of Tissue-Based Testing

The Infection Diagnostic Market represents an adjacent application area for bronchoscopic sampling, particularly when pulmonary infections require tissue or fluid specimens for laboratory evaluation. Although EBUS-TBNA is principally associated with lung cancer diagnosis and mediastinal staging, bronchoscopic procedures can contribute to diagnosing selected infectious and inflammatory conditions involving lymph nodes and pulmonary structures. Obtaining appropriate specimens can help laboratories conduct microbiological, pathological, and molecular investigations. The broader shift toward rapid and accurate infectious-disease diagnostics is encouraging healthcare providers to use advanced sampling and laboratory technologies that can provide actionable results. EBUS-guided procedures may be particularly relevant when lymph-node sampling is clinically indicated and infection is part of the differential diagnosis. The market opportunity is therefore connected to broader improvements in molecular microbiology, pathology, specimen processing, and bronchoscopic imaging. Adoption depends on clinical indication, physician expertise, laboratory capabilities, reimbursement, and the ability to distinguish infectious applications from EBUS's much larger oncology-focused use.

Ambulatory Surgical Centers - Moving Bronchoscopic Care Toward Outpatient Settings

The Ambulatory Surgical Centers (ASCs) Market offers potential for EBUS biopsy as healthcare systems increasingly seek efficient outpatient pathways for appropriate diagnostic procedures. ASCs can provide specialized procedural infrastructure, anesthesia support, recovery areas, and streamlined scheduling, potentially improving convenience and resource utilization. EBUS procedures that meet patient-selection, clinical, anesthesia, and facility requirements may be performed in outpatient environments, although the suitability of an ASC depends on individual clinical circumstances and local capabilities. Growth of outpatient care can encourage investments in compact bronchoscopic systems, single-use accessories, digital imaging, and efficient specimen-handling workflows. Single-use respiratory technologies are gaining attention as manufacturers address infection-control and reprocessing considerations. Olympus' 2026 respiratory portfolio expansion, including single-use bronchoscopes and its planned distribution of a portable single-use cryobiopsy system, reflects this broader movement toward flexible respiratory procedural technologies. However, ASCs require trained personnel, appropriate emergency capabilities, pathology coordination, and adequate procedure volumes.

Market Segmentations

Product

• EBUS Scopes
• EBUS Needles
• Ultrasound Processors and Imaging Systems
• Accessories

Application

• Cancer Diagnostic
• Infection Diagnostic
• Others

End Use

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics

States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All the Key players have been covered

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis:

• GE Healthcare
• Siemens Healthcare Private Limited
• Koninklijke Philips N.V.
• Boston Scientific Corporation
• Olympus Corporation
• Cook Group Incorporated
• FUJIFILM Holdings Corporation
• Medi-Globe Technologies GmbH

Report Details: